Literature DB >> 17663289

An update on the treatment of precocious puberty in McCune-Albright syndrome and testotoxicosis.

Nadine Haddad1, Erica Eugster.   

Abstract

McCune-Albright syndrome and testotoxicosis are rare forms of peripheral precocious puberty. Our understanding of the pathophysiology and mechanism of these diseases has significantly increased following identification of their underlying molecular etiology. However, their treatment remains challenging. We provide a review of the various treatment modalities used in both conditions with an update on recent trials using novel and promising pharmacological agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17663289     DOI: 10.1515/jpem.2007.20.6.653

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  4 in total

1.  Combined treatment with ketoconazole and cyproterone acetate in a boy with McCune-Albright syndrome and peripheral precocious puberty.

Authors:  M F Messina; T Arrigo; M Wasniewska; F Lombardo; G Crisafulli; G Salzano; F De Luca
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

2.  Macroorchidism in an Indian boy with McCune-Albright syndrome.

Authors:  Vaishakhi T Rustagi; Vaman V Khadilkar; Anuradha V Khadilkar; Arun S Kinare
Journal:  Indian J Pediatr       Date:  2011-02-15       Impact factor: 1.967

3.  Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome.

Authors:  Emily K Sims; Sally Garnett; Franco Guzman; Françoise Paris; Charles Sultan; Erica A Eugster
Journal:  Int J Pediatr Endocrinol       Date:  2012-09-22

Review 4.  Clinical Characteristics and Management of Patients With McCune-Albright Syndrome With GH Excess and Precocious Puberty: A Case Series and Literature Review.

Authors:  Xiao Zhai; Lian Duan; Yong Yao; Bing Xing; Kan Deng; Linjie Wang; Feng Feng; Zhiyong Liang; Hui You; Hongbo Yang; Lin Lu; Shi Chen; Renzhi Wang; Hui Pan; Huijuan Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-29       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.